FDA approves two new indications for Gilead Sciences' Harvoni to treat chronic hepatitis C
Gilead Sciences has secured approval from the US Food and Drug Administration (FDA) for additional indications for Harvoni to treat chronic hepatitis C patients with advanced liver disease. The new indications allow to treat liver transplant recipients with genotype 1 or 4 infection without cirrhosis or with compensated cirrhosis, and for genotype 1-infected patients with decompensated cirrhosis.
Click on this link for more information.
